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Abstract 
 
A new series of hybrid PDMP analogues, based both on PDMP and styryl analogues of 
natural ceramide, has been synthesised from D-serine.  The synthetic route was developed 
such that future introduction of different aryl groups is straightforward.  Biological 
evaluation, both in vitro on rat liver Golgi fractions as well as in HEK-293 and COS-7 cells, 
revealed two lead compounds with comparable inhibitory potency as PDMP, which could be 
elaborated to more potent inhibitors.   
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1.  Introduction 
 
A plethora of biological effects has been assigned to sphingolipids (SLs) over the last two 
decades.  Whereas SLs initially were regarded as inert structural components of cell 
membranes, it has now become clear that they play an important role in the regulation of a 
myriad of cellular processes including cellular differentiation, growth, adhesion, senescence, 
apoptosis and signal transduction.1  It is obvious that disruption of this fragile cellular 
equilibrium, for example by impaired lysosomal degradation of SLs, could have severe 
pathophysiological consequences.  Lysosomal storage diseases, such as Gaucher and Tay-
Sachs diseases, are caused by the defective catabolism of glycosphingolipids (GSLs), 
resulting in substrate accumulation. 2  
 
Since glucosylceramide (GlcCer; 1; Figure 1) acts as a hub for the synthesis of more complex 
GSLs, it has been suggested3 that partial reduction of the biosynthesis of GlcCer might offer a 
valuable strategy for treatment of storage diseases such as Gaucher disease and other 
sphingolipid storage diseases. 
 
Figure 1 
 
PDMP4 (D-threo-(1R,2R)-phenyl-2-decanoylamino-3-morpholino-1-propanol; 2) and related 
compounds5 have been developed as potent inhibitors of GlcCer synthase.  Surprisingly, only 
the D-threo isomer specifically inhibits GlcCer synthase.6  Furthermore, it was shown that 
elongation of the acyl chain from decanoyl to palmitoyl5a and introduction of electron 
donating aromatic substituents5b drastically enhanced the inhibitory capacity.  Moreover, a 
pyrrolidino head group was proposed to be the best mimic of the sugar transition state. 
 
In our approach we aimed at the synthesis of hybrid structures based on styryl analogues (3) 
of natural ceramides.  It was indeed previously shown that such analogues are recognised by 
GlcCer synthase7 and subsequently metabolised to the glucosylated form.  Our primary 
concern was whether these hybrid analogues would still exhibit biological activity.   
 
Our strategy focused mainly on the elaboration of a synthetic route towards a single advanced 
intermediate for introduction of the aryl moiety by Sonogashira coupling between a terminal 
alkyne and an appropriate aryl iodide, thereby avoiding reworking of the entire synthetic 
scheme for each compound.  Throughout the synthetic scheme, we gained access to a number 
of structural analogues which could provide more insight into the structure-activity 
relationship of this class of compounds. 
 
 
2.  Results and Discussion 
2.1.  Chemistry 
 
The known Garner aldehyde (derived in 5 steps from D-serine8) served as a chiral building 
block since it allows good control of stereochemistry in nucleophilic additions and it has 
shown to be configurationally stable.9  Indeed, addition of the appropriate lithium acetylide to 
the aldehyde under chelating conditions (ZnBr2) yielded predominantly threo-adducts 4 and 
5b (41% and 44% isolated yields respectively; threo:ertythro 9:1; Scheme 1).10  Removal of 
the TMS group from threo-4 with TBAF produced terminal alkyne threo-5a (93%).  
Subsequent opening of the oxazolidine ring with 90% acetic acid or p-TsOH in MeOH 
followed by selective silylation of the primary alcohol gave the protected sphingosine 
analogues 7a (83% from threo-5a) and 7b (59% from threo-5b).  Since it had become clear 
from preliminary experiments that a double amino-protective strategy would be crucial for 
successful elaboration to the desired compounds, acid mediated oxazolidine ring formation 
followed by desilylation allowed access to alcohols 9a (94% from 7a) and 9b (76% from 7b).  
Sonogashira coupling of terminal alkyne 9a with iodobenzene gave alcohol 9b in excellent 
yield (99%).11 
 
Scheme 1 
 
Although we succeeded in converging both synthetic pathways at this point, it would still be 
more convenient to introduce the aromatic ring at a later stage to avoid the separate 
introduction of amine substituents for each individual aryl analogue.  Therefore, both primary 
alcohols 9a and 9b were converted to the respective tosylates 10a (94%) and 10b (64%).  The 
lower yield of 10b might be ascribed to decomposition during work-up.  Indeed, the reaction 
mixture became more complex when solvent removal was carried out at 40-50°C.  In contrast, 
when the temperature was strictly kept below 35°C, few side products were observed.  The 
nucleophilic nature of the tert-Boc group,12 susceptible to formation of a bicyclic oxazolidine-
oxazolidinone,13 might be responsible for this phenomenon. 
 
Treatment of 10a and 10b with the appropriate nucleophile in DMF at elevated temperatures 
gave access to key intermediates 11a-e (62-99%).  Sonogashira coupling of 11d with 
iodobenzene proceeded smoothly to produce 11c (93%). 
 
Acid mediated deprotection of 11a-e followed by acylation gave alkyne analogues 13a-d (48-
89%) and 18 (60%; Scheme 2). Unfortunately, Sonogashira coupling of 18 with iodobenzene 
showed to be a bridge too far since it failed to give alkyne 13c in satisfactory yields (32%).  
Therefore, key intermediate 11d should be regarded as a solid base for future introduction of 
alternative aryl substituents.  Reduction of 13d under Staudinger conditions gave amine 13e 
in excellent yield (97%).  Since treatment of 13a and 13b with Na/NH3 produced complex 
mixtures, we opted to reduce the alkyne with Red-Al®, although we were aware that 
controversial results14 had been obtained in the presence of amides.  Unfortunately, upon 
treatment of amides 13a, 13b and 13e with Red-Al® at -78°C, the corresponding E-styryl 
ceramines 14a (60%) 14b (quant.) and 14c (45%) were isolated as the sole reaction products.  
Nonetheless, comparison of the biological activities of these amines with the amide 
counterparts could provide insight into the role of the amide function in binding to GlcCer 
synthase since no D-threo ceramines have been evaluated to date as potential inhibitors. 
 
Scheme 2 
 In order to circumvent the reduction of the amide group, amines 12a-c were first treated with 
Red-Al® at -78°C followed by acylation with p-nitrophenylpalmitoate to give access to PDMP 
analogues 16a-c (84, 78 and 71% respectively). 
 
Stereochemical assignment of the threo configuration was achieved by treatment of amine 
13e with triphosgene yielding oxazolidinone 19 (88%).  Based on the small coupling constant 
3J5,6 = 3.42 Hz, an axial-axial orientation can be excluded (Scheme 3, conformer erythro-
19A).  The remaining question was whether C(5)H was in axial or equatorial position.  The 
values of the coupling constants 3J4a,5 = 6.71 Hz and 3J4b,5 = 5.13 Hz indicate a pseudo-axial-
axial orientation.  Selective irradiation of C(6)H (δ = 5.40 ppm) and NOEDIF observation 
showed an increase of C(5)H (5.0 %) and a weaker, but still significant increase of C(4)Hb (2 
%).  Only conformer threo-19D would give a NOE contact between C(6)H and C(4)Hb 
indicating a cis-relationship of the substituents on C(5) and C(6).  Performing these 
experiments at higher temperature (60 °C) did not affect the coupling constant, demonstrating 
the presence of a single conformer. 
 
Scheme 3 
 
 
2.2.  Biological evaluation 
 
In a preliminary, exploratory in vitro assay, using a short acyl chain analogue of ceramide, N-
[6-[(7-nitrobenzo-2-oxa-1,3-diazol-4-yl)amino]hexanoyl]D-erythro-sphingosine (C6-NBD-D-
erythro-ceramide), as substrate for GlcCer synthase (Figure 2), compounds 13a,b,d,e, 14a-c, 
16a-c, 18 and PDMP were evaluated as potential inhibitors of GlcCer synthase in rat liver 
Golgi membrane homogenates.  Moreover, specificity of inhibition towards GlcCer synthase 
was assessed by monitoring sphingomyelin (SM) synthesis from C6-NBD-D-erythro-
ceramide.15  Indeed, toxicity of PDMP analogues has been associated with increased 
intracellular ceramide (Cer) levels.5b  Inhibition of sphingomyelin synthase (SM synthase),16 
as well as different mechanisms, have been proposed5a,5b to cause this phenomena. 
 
Figure 2 
 
Interestingly, almost all compounds showed some inhibition of GlcCer synthesis (Figure 2A).  
Comparison of the inhibitory activities of the morpholino series 13a, 14a and 16a clearly 
shows that the presence of an amide carbonyl increases inhibitory activity.  Moreover, alkyne 
13a and E-alkene 16a seem to be equally potent.  In contrast, piperidine analogues 13b and 
16b show a small difference in favour of the E-alkene analogue.   
 
Surprisingly, analogue 18 revealed that the presence of the aromatic ring was not a 
prerequisite for inhibitory activity.  Furthermore, terminal alkyne 18 demonstrated 
comparable potency with respect to its aromatic E-alkene counterpart 16c.  Data for ceramine 
14b confirmed the necessity of the amide for distinct inhibitory activity although this 
analogue still reduced GlcCer synthesis by 65% at 25 µM.  By switching to non-cyclic 
nitrogen substituents as in compounds 13d, 13e and 14c, the inhibitory activity drastically 
dropped, thereby clearly indicating the requirement of cyclic amines as sugar transition state 
mimics, as previously assumed.5a  In agreement with published results for PDMP analogues,5a 
data for 16a, 16b and 16c demonstrated that a pyrrolidine substituent on -C(1) is undoubtedly 
favourable over a morpholino or piperidino head group. 
 
Most analogues showed a concentration-dependent decrease in SM synthesis similar to 
PDMP, as depicted in Figure 2B.  However, treatment with 25 or 50 µM concentrations did 
not significantly affect SM synthesis, except for 13d, which induced a substantial decrease in 
SM synthesis.  When higher molar concentrations were applied, a significant decrease in SM 
synthesis was noticed, except for 13b, which showed an increase in SM at all inhibitor 
concentrations. 
 
An interesting feature was noticed in the assays of compounds 13e and 14c.  Apart from the 
expected SLs, a new “upper band” was observed on TLC with an Rf which was slightly larger 
than the Rf of C6-NBD-ceramide.  It is difficult to speculate on the nature of this metabolite, 
but based on its apolar behaviour, one could assume that acylation on C(1) by 1-O-acyl 
transferase17 might have occurred, thereby yielding a compound with larger Rf than C6-NBD-
ceramide.  Further investigation will be necessary to reveal this metabolite’s identity. 
 
In a subsequent set of assays, the biological profile of the most potent inhibitors, 16c and 18, 
was examined in detail both in vitro on rat liver Golgi fractions and in HEK-293 cells (Figure 
3).  Both compounds were equally as potent as PDMP in inhibiting GlcCer synthase in Golgi 
fractions, as depicted in Figure 3A.  The calculated IC50 values from these experiments for 
PDMP, 16c and 18 are 5.33, 5.44 and 4.23 µM respectively.  The value for PDMP is in good 
agreement with published data (5 µM).6  Within the concentration range of this assay, neither 
analogues affected SM synthesis (Figure 3B). 
 
Figure 3 
 
Living cell inhibition was assessed by incubating HEK-293 cells for 3 h in the presence of 10, 
25 and 50 µM of analogues 16c and 18, together with C6-NBD-ceramide (Figure 4A).  Again, 
both compounds inhibited GlcCer synthesis to the same extent as PDMP.  Data concerning 
SM synthesis in HEK-293 cells correlate well with findings in vitro (Figure 4B).  Even at 50 
µM no effect on SM synthesis was observed. 
 
Figure 4 
 
We next examined de novo synthesis of other SLs, using 3H-serine as a precursor, in HEK-
293 (Figure 5) and COS-7 cells (data not shown), following pre-treatment with the inhibitors.  
GlcCer synthesis was moderately inhibited in both cell lines. While values for 16c (62 % of 
control) were comparable to PDMP (52% of control), 18 (37 % of control) proved to be 
somewhat more effective.  Lactosylceramide (LacCer) levels slightly decreased upon 
treatment with both PDMP and 16c (48% of control), whereas no effect could be observed 
upon incubation with 18 (118% of control).  Cer levels substantially increased (up to two-
fold) upon treatment with the inhibitors.  In contrast, SM levels were only very slightly 
affected by both 16c (81% of control) and 18 (118% of control) at this concentration.  These 
findings indicate that inhibition of SM synthesis is not responsible for the observed ceramide 
accumulation in these cell lines. Therefore, other ceramide salvage pathways must be 
involved.  The only way to disclose the true nature of the specific enzyme(s) involved in 
ceramide accumulation is by rigorously monitoring cellular levels of all known SLs. 
 
Figure 5 
 
 
 
3.  Conclusion 
 
We have developed a flexible synthetic route towards a new series of hybrid PDMP 
analogues.  A key reaction in our approach was the Sonogashira coupling between an aryl 
iodide and a terminal alkyne intermediate.  The influence of the synthesized compounds on 
GlcCer and SM synthesis was evaluated both in vitro and in living cells.  Optimal inhibitory 
activity was observed when a pyrrolidine head group was combined with an amide-linked 
fatty acid.  Interestingly, by replacing the E-styrene moiety by a terminal alkyne an equally 
potent analogue was obtained.  This simplified terminal alkyne PDMP analogue provides a 
solid lead for future introduction of different aryl groups in the search for PDMP analogues 
with enhanced biological activity. 
 
 
4.  Experimental Part 
 
4.1. Chemistry 
 
4.1.1.  General 
 
All reactions were carried out under inert (N2) atmosphere.  Precoated Macherey-Nagel 
(Düren, Germany) silica gel F254 plates were used for TLC and spots were examined under 
UV light at 254 nm and/or revealed by sulphuric acid-anisaldehyde spray or 
phosphomolybdic acid spray.  All purifications were performed with ICN silica gel (63-200 
µM, ICN, Asse Relegem, Belgium).  NMR spectra were obtained with a Varian Mercury 300 
or 500 spectrometer (Varian, Palo Alto, California, USA).  Chemical shifts are given in parts 
per million (δ) relative to residual solvent peak.  All signals assigned to amino and hydroxyl 
groups were exchangeable with D2O.  Numbering for 1H assignment is based on the IUPAC 
name of the compounds.  Structural assignment was confirmed with COSY, HMQC and/or 
NOEDIF if necessary.  Exact mass measurements were performed on a 
quadrupole/orthogonal-acceleration time-of-flight (Q/oaTOF) tandem mass spectrometer 
(qTof2, Micromass, Manchester, UK) equipped with a standard electrospray ionisation (ESI) 
interface.  Samples were infused in a 2-propanol/water (1:1) mixture at 3 µL/min.  Optical 
rotations were measured with a Perkin-Elmer 241 polarimeter. 
 4.1.2. (R)-tert-Butyl 4-((R)-1’-hydroxy-3’-(trimethylsilyl)prop-2’-ynyl)-2,2-
dimethyloxazolidine-3-carboxylate (threo-4)  
To a solution of trimethylsilylacetylene (12.53 mL, 88 mmol, 1.66 eq.) in anhydrous Et2O 
(450 mL) at -78°C, nBuLi (50 mL of 1.6M in hexanes, 80 mmol, 1.51 eq.) was added 
dropwise.  The mixture was stirred for 1 h at 0°C and 1 h at room temperature and was 
subsequently cooled to 0°C.  After addition of ZnBr2 (23.89 g, 106.1 mmol, 2 eq.), the 
reaction mixture was stirred at room temperature for 1 h and subsequently cooled to -78°C.  
D-Garner’s aldehyde (12.16 g, 53.07 mmol) was dissolved in anhydrous Et2O (50 mL), cooled 
to -78°C and added dropwise to the above solution.  The mixture was allowed to reach room 
temperature overnight and after cooling to 0°C, saturated NH4Cl (100 mL) was added in one 
portion.  The aqueous layer was extracted with Et2O (2 x 100 mL).  The combined organic 
phase was dried over MgSO4, and the solvent was removed under reduced pressure.  The 
residue was purified by flash chromatography (hexanes:EtOAc 9:1) affording threo-4 (7.167 
g, 41%) and a mixture of erythro/threo-4 (4.736 g, 27%), both as a slightly yellow oil.  1H 
(300 MHz; DMSO-d6) δ: 0.11 (s, 9H, (CH3)3Si), 1.35 – 1.52 (m, 15H, 2 x -CH3 and tert-
butyl), 3.75 - 3.85 (m, 1H, -C(4)H),  3.95 (td, 1H, J = 3.51 and 9.08 Hz, -C(5)Ha), 4.05 (dd, 
1H, J = 5.28 and 8.21 Hz, -C(5)Hb), 4.68 (m, 1H, -C(4)CHOH), 5.77 (m, 1H, -C(4)CHOH); 
13C (75 MHz; DMSO-d6) δ: -0.30, -0.20, 23.51, 24.77, 25.54, 26.40, 27.87, 60.12, 60.65, 
61.56, 63.65, 64.09, 79.24, 79.58, 93.58, 93.94, 106.10, 106.27, 151.88, 151.19; exact mass 
(ESI-MS) calculated for C16H30NO4Si [M+H]+: 328.1944, found: 328.1943. 
 
4.1.3.  (R)-tert-Butyl 4-((R)-1’-hydroxyprop-2’-ynyl)-2,2-dimethyloxazolidine-3-
carboxylate (5a) 
 
TBAF (38.5 mL of a 1M solution in THF, 38.5 mmol, 1.2 eq.) was added to a solution of 
threo-4 (10.5 g, 32.05 mmol) in THF (10 mL).  The solution was stirred for 1 h at room 
temperature and the solvent was subsequently removed under reduced pressure.  The residue 
was dissolved in EtOAc (50 mL) and washed with saturated NaHCO3 (50 mL).  The aqueous 
layer was extracted with EtOAc (2 x 50 mL).  The combined organic phase was dried over 
MgSO4 and the solvent was removed under reduced pressure.  The residue was purified by 
flash chromatography (hexanes:EtOAc 4:1) yielding threo-5a (7.61 g, 93%) as a white solid.  
1H (300 MHz; DMSO-d6) δ: 1.35 – 1.42 (m, 12H, -CH3 and tert-butyl), 1.50 (s, 3H, -CH3), 
3.20 (d, 1H, J = 4.4 Hz, alkyne H), 3.81 (m, 1H, -C(4)H), 3.94 (m, 1H, -C(5)Ha), 4.02 (dd, 
1H, J = 2.64 and 9.09 Hz, -C(5)Hb), 4.61 (br s, 1H, -C(4)CHOH), 5.71 (m, 1H, -C(4)CHOH);  
13C (75 MHz; DMSO-d6) δ: 23.17, 24.49, 25.77, 26.58, 60.18, 60.66, 60.96, 63.39, 63.81, 
75.59, 75.77, 79.23, 79.65, 83.50, 93.63, 93.94, 151.31, 152.00; exact mass (ESI-MS) 
calculated for C13H21NO4Na [M+Na]+: 278.1368, found: 278.1364. 
 
 
4.1.4.  (R)-tert-Butyl 4-((R)-1’-hydroxy-3’-phenylprop-2’-ynyl)-2,2-dimethyloxazolidine-
3-carboxylate (threo-5b) 
 
To a stirred and cooled (0°C) solution of lithium phenylacetylide (42.7 mL of a 1M solution in 
THF, 42.7 mmol, 2 eq.) in anhydrous Et2O (200 mL), ZnBr2 (10.11 g, 44.88 mmol, 2.1 eq.) 
was added and the mixture was stirred for 1 h at 0°C and 1 h at room temperature and was 
subsequently cooled – 78°C.  D-Garner’s aldehyde (4.90 g, 21.37 mmol) was dissolved in 
anhydrous Et2O (25 mL), the resulting solution cooled to -78°C and added dropwise to the 
above solution.  The mixture was allowed to reach room temperature overnight and after 
cooling to 0°C, treated with sat. NH4Cl (50 mL).  After separation of the phases, the aqueous 
layer was extracted with Et2O (2 x 100 mL) and the combined organic phase was dried over 
MgSO4.  After removal of the solvent under reduced pressure, the residue was purified by 
flash chromatography (hexanes:EtOAc 9:1  85:15) affording threo-5b (3.125 g; 44%) and a 
mixture of erythro- and threo-5b (2.014 g, 28%), both as a yellow oil.  1H (300 MHz; DMSO-
d6) δ: 1.46 – 1.49 (m, 12H, -CH3 and tert-butyl), 1.50 (s, 3H, -CH3), 3.85 – 4.06 (m, 2H, -
C(4)H and –C(5)Ha), 4.14 (dd, 1H, J = 2.35 and 9.09 Hz, –C(5)Hb), 4.82- 4.92 (m, 1H, -
C(4)CHOH), 5.88 (m, 1H, -C(4)CHOH), 7.35 – 7.40 (m, 5H, arom. H); 13C (75 MHz; 
DMSO-d6) δ: 25.78, 27.59, 60.68, 61.11, 63.65, 78.93, 83.84, 89.59, 93.34, 122.12, 127.87, 
128.06, 131.02, 151.44; exact mass (ESI-MS) calculated for C19H26NO4 [M+H]+: 332.1862, 
found: 332.1864. 
 
4.1.5.  tert-Butyl (2R,3R)-1,3-dihydroxypent-4-yn-2-ylcarbamate (6a) 
 
A solution of threo-5a (7.57 g, 29.65 mmol) in 90% acetic acid was stirred for 5 h at 60°C.  
The solvent was removed under reduced pressure, and the residue was coevaporated twice 
with isooctane (25 mL).  The residue was purified by flash chromatography (hexanes:EtOAc 
1:1) yielding 6a (5.935 g, 93%) as a slightly yellow, viscous oil.  1H (300 MHz; DMSO-d6) δ: 
1.36 (s, 9H, tert-butyl), 3.21 (d, 1H, J = 2.06 Hz, alkyne H), 3.32 – 3.52 (m, 3H, -C(1)H2 and 
-C(2)H), 4.28 – 4.35 (m, 1H, -C(3)H), 4.61 (t, 1H, J = 5.57 Hz, -C(1)OH)), 5.38 (d, 1H, J = 
6.45 Hz, -C(3)OH), 6.24 (d, 1H, J = 7.63 Hz, -NH); 13C (75 MHz; DMSO-d6) δ: 28.20, 
56.98, 59.62, 59.95, 75.03, 77.80, 84.25, 155.41; exact mass (ESI-MS) calculated for 
C10H17NO4Na [M+Na]+: 238.1055, found: 238.1047. 
 
4.1.6.  tert-Butyl (2R,3R)-1,3-dihydroxy-5-phenylpent-4-yn-2-ylcarbamate (6b) 
 
To a solution of threo-5b (5.91 g, 17.83 mmol) in MeOH (70 mL), p-TsOH.H2O (339 mg, 
1.783 mmol, 0.1 eq.) was added, and the resulting solution was stirred for 36 h at room 
temperature.  TEA (3 mL) was added to the cooled (0°C) solution, and the solvent was 
removed in vacuo.  The residue was dissolved in EtOAc (100 mL) and the resulting solution 
extracted with sat. NaHCO3 (2 x 25 mL) and brine (25 mL).  After drying over MgSO4, the 
solvent was removed under reduced pressure, and the residue was purified by column 
chromatography (hexanes:EtOAc 3:2) producing 6b (3.64 g, 70%) as a white foam.  1H (300 
MHz; DMSO-d6) δ: 1.38 (s, 9H, tert-butyl), 3.25 – 3.68 (m, 3H, -C(1)H2 and -C(2)H), 4.56 
(dd, 1H, J = 3.82 and 6.75 Hz, -C(3)H), 4.64 (t, 1H, J = 5.57 Hz, -C(1)OH), 5.47 (d, 1H, J = 
6.45 Hz, -C(3)OH), 6.36 (d, 1H,  J = 8.50 Hz, -NH), 7.32 – 7.42 (m, 5H, arom. H); exact mass 
(ESI-MS) calculated for C16H22NO4 [M+H]+: 292.1549, found: 292.1545. 
 
Typical procedure for silylation of 6a and 6b.  TBDPSCl (9.5 mmol) was added dropwise 
to a cooled solution (0°C) of 6a or 6b (10 mmol), imidazole (30 mmol) and 4-DMAP (cat.) in 
anhydrous DMF (20 mL).  The mixture was stirred overnight and the solvent was 
subsequently removed under reduced pressure.  The residue was partitioned between Et2O (25 
mL) and sat. NaHCO3 (12 mL).  After separation of the phases, the organic layer was washed 
with sat. NaHCO3 (12 mL) and brine (12 mL).  The organic phase was dried over MgSO4, and 
the solvent was removed under reduced pressure.  The residue was purified by flash 
chromatography (hexanes:EtOAc 9:1) affording 7a and 7b as very viscous, slightly yellow 
oils. 
 
4.1.7.  tert-Butyl (2R,3R)-1-(tert-butyldiphenylsilyloxy)-3-hydroxypent-4-yn-2-
ylcarbamate (7a) 
 10.8 g (89%).  1H (300 MHz; DMSO-d6) δ: 0.97 (s, 9H, tert-butyl silyl), 1.37 (s, 9H, tert-
butyl), 3.25 (d, 1H, J = 2.05 Hz, alkyn H), 3.60 – 3.82 (m, 3H, -C(1)H2 and –C(2)H), 4.39 – 
4.47 (m, 1H, -C(3)H), 5.49 (d, 1H, J = 6.74 Hz, -C(3)OH), 6.41 (d, 1H, J =  8.21 Hz, -NH), 
7.35 – 7.44 (m, 4H, arom. H), 7.59 – 7.65 (m, 6H, arom. H); 13C (75 MHz; DMSO-d6) δ: 
18.82, 26.53, 28.19, 56.90, 60.04, 62.56, 75.30, 77.77, 83.89, 127.78, 129.77, 133.01, 135.02, 
155.39; exact mass (ESI-MS) calculated for C26H35NO4SiNa [M+Na]+: 476.2233, found: 
476.2234. 
 
4.1.8.  tert-Butyl (2R,3R)-3-hydroxy-1-(tert-butyldiphenylsilyloxy)-5-phenylpent-4-yn-2-
ylcarbamate (7b) 
 
4.82 g (84%).  1H (300 MHz; DMSO-d6) δ: 1.07 (s, 9H, tert-butyl silyl), 1.37 (s, 9H, tert-
butyl), 3.66 – 3.73 (m, 1H, -C(1)Ha), 3.76 – 3.92 (m, 2H, -C(1)Hb and C(2)H), 4.56 – 4.67 (m, 
1H, -C(3)H), 5.48 – 5.64 (m, 1H, -C(3)OH), 6.56 (d, 1H, J = 7.92 Hz, -NH), 7.28 – 7.48 (m, 
10H, arom. H), 7.58 – 7.67 (m, 5H, arom. H); 13C (75 MHz; DMSO-d6) δ: 18.81, 26.54, 
28.20, 57.10, 60.86, 62.83, 77.75, 84.00, 89.80, 122.24, 127.77, 128.50, 129.76, 131.27, 
133.00, 133.03, 135.01, 155.46; exact mass (ESI-MS) calculated for C32H40SiNO4 [M+H]+: 
530.2727, found: 530.2721.  
 
General procedure for the preparation of oxazolidines 8a and 8b.  To a solution of 7a or 
7b (10 mmol) in a mixture of acetone/2,2-dimethoxypropane (2.6:1, 40 mL), p-TsOH.H2O (5 
mol%) was added in one portion and the reaction was refluxed for 6 h.  Removal of the 
solvent under reduced pressure, followed by flash chromatography (hexanes:EtOAc 95:5) 
afforded 8a and 8b as colourless oils. 
 
4.1.9.  (4S,5R)-tert-Butyl 5-ethynyl-4-((tert-butyldiphenylsilyloxy)methyl)-2,2-
dimethyloxazolidine-3-carboxylate (8a) 
 
9.95 g (98%) 1H (300 MHz; DMSO-d6) δ: 0.96 (s, 9H, tert-butyl silyl), 1.15 – 1.44 (m, 12H, 
tert-butyl and –CH3), 1.62 (s, 3H, -CH3), 3.48 – 3.85 (m, 3H, alkyne H and –C(4)CH2), 3.90 – 
4.05 (m, 1H, -C(4)H), 4.82 – 4.97 (m, 1H, -C(5)H),  7.35 – 7.63 (m, 10H, arom. H); 13C (75 
MHz; DMSO-d6) δ: 18.77, 26.50, 26.84, 27.24, 27.77, 61.12, 62.29, 64.27, 64.51, 65.33, 
65.94, 77.03, 79.48, 79.79, 82.43, 82.92, 94.72, 95.27, 127.91, 129.98, 132.43, 134.99, 
150.53, 151.01; exact mass (ESI-MS) calculated for C35H45SiO4N [M+Na]+: 516.2546, found: 
516.2554.  
 
4.1.10.  (4R,5R)-tert-Butyl 4-((tert-butyldiphenylsilyloxy)-methyl)-2,2-dimethyl-5-(2-
phenylethynyl) oxazolidine-3-carboxylate (8b) 
 
4.22 g (84%).  1H (300 MHz; DMSO-d6) δ: 0.95 – 1.05 (s, 9H, tert-butyl silyl), 1.18 – 1.50 
(m, 12H, tert-butyl and –CH3), 1.67 (s, 3H, -CH3), 3.60 – 3.92 (m, 2H, -C(4)H and -
C(4)CHa), 3.98 – 4.10 (m, 1H, -C(4)CHb), 5.08 – 5.20 (m, 1H, C(5)H), 7.35 – 7.50 (m, 10H, 
arom. H), 7.58 – 7.65 (m, 5H, arom. H); 13C (75 MHz; DMSO-d6) δ: 18.79, 26.55, 27.82, 
61.32, 62.17, 64.26, 64.51, 65.23, 65.82, 77.03, 79.33, 79.64, 87.37, 87.82, 95.78, 96.02, 
121.36, 127.92, 128.75, 129.09, 130.00, 131.33, 132.52, 135.07, 150.55, 151.03; exact mass 
(ESI-MS) calculated for C35H45SiO4N [M+H]+: 570.3040, found: 570.3043.  
 
General procedure for the preparation of alcohols 9a and 9b.  To a solution of 8a or 8b 
(10 mmol) in THF (50 mL), TBAF (15 mmol) was added in one portion, and the solution was 
stirred for 75 min at room temperature.  The solvent was subsequently removed under 
reduced pressure, and the residue was dissolved in EtOAc (100 mL).  The organic layer was 
washed with saturated NaHCO3 (3 x 25 mL), dried over MgSO4 and concentrated under 
reduced pressure.  The residue was purified by column chromatography (hexanes:EtOAc 4:1) 
yielding 9a and 9b as white solids. 
 
4.1.11.  (4R,5R)-tert-Butyl 5-ethynyl-4-(hydroxymethyl)-2,2-dimethyloxazolidine-3-
carboxylate (9a) 
 
4.95 g (96%).  1H (300 MHz; DMSO-d6) δ: 1.40 (s, 9H, tert-butyl), 1.60 – 1.63 (m, 6H, 2 x –
CH3), 3.15 – 3.26 (m, 1H, -C(4)CHa), 3.45 – 3.53 (m, 1H, -C(4)CHb), 3.58 (d, 1H, J = 2.35, 
alkyne H), 3.76 - 3.90 (m, 1H, -C(4)H), 4.72 – 4.78 (m, 1H, -C(5)H), 5.05 – 5.15 (m, 1H, -
C(4)CH2OH);  13C (75 MHz; DMSO-d6) δ: 25.51, 26.84, 27.19, 28.01, 59.50, 60.24, 65.05, 
65.32, 65.48, 65.89, 76.79, 79.42, 79.88, 83.60, 94.60, 94.95, 150.74, 151.07; exact mass 
(ESI-MS) calculated for C13H21NO4Na [M+Na]+: 278.1368, found: 278.1364. 
 
4.1.12.   (4R,5R)-tert-Butyl 4-(hydroxymethyl)-2,2-dimethyl-5-(2-
phenylethynyl)oxazolidine-3-carboxylate (9b) 
 
2.22 g (91%).  1H (300 MHz; DMSO-d6) δ: 1.41 (m, 9H, tert-butyl), 1.44 (s, 3H, –CH3), 1.68 
(s, 3H, -CH3), 3.24 – 3.36 (m, 1H, -C(4)CHa), 3.51 – 3.62 (m, 1H, -C(4)CHb), 3.88 - 4.20 (m, 
1H, -C(4)H), 5.02 (d, 1H, J = 1.53 Hz, -C(5)H), 5.06 – 5.17 (br s, 1H, -C(4)CH2OH), 7.34 – 
7.45 (m, 5H, arom. H); 13C (75 MHz; DMSO-d6) δ: 25.61, 27.06, 27.94, 59.51, 60.25, 65.16, 
66.17, 66.49, 79.42, 79.81, 84.87, 89.01, 94.53, 94.78, 121.49, 128.70, 128.94, 131.21, 
157.75; exact mass (ESI-MS) calculated for C19H26O4N [M+H]+: 332.1862, found: 332.1865. 
 
Conversion of 9a to 9b.  To a solution of 9a (651 mg, 2.55 mmol) and PdCl2(PPh3)2 (36 mg, 
51 µmol, 2 mol%) in piperidine (5 mL), iodobenzene (429 µL, 3.82 mmol, 1.5 eq.) was added 
and the mixture was stirred overnight at 70°C.  The solvent was subsequently removed under 
reduced pressure and the residue was purified by column chromatography rendering 
(hexanes:EtOAc 4:1) 9b (841 mg, 99%) as a white solid. 
 
General procedure for the preparation of tosylates 10a and 10b.  Solid p-TsCl (3 mmol) 
was added to an ice-cold solution of 9a or 9b (1 mmol) in anhydrous pyridine (1 mL) and 
after stirring for 35 h at room temperature, the reaction mixture was evaporated to dryness at 
high vacuum (< 35°C for 10a, 40 – 50°C for 10b).  The residue was purified by column 
chromatography (hexanes:EtOAc 85:15) to yield 10a and 10b as white solids. 
 
4.1.13.  ((4R,5R)-3-(tert-Butoxycarbonyl)-5-ethynyl-2,2-dimethyloxazolidin-4-yl)methyl 
4-methylbenzenesulfonate (10a) 
 
1.85 g (94%).  1H (300 MHz; DMSO-d6) δ: 1.34 (s, 9H, tert-butyl), 1.58 – 1.61 (m, 6H, 2 x -
CH3), 2.41 (s, 3H, tosyl -CH3), 3.64 (d, 1H, J = 2.34 Hz, alkyne H), 4.00 – 4.10 (m, 3H, -
C(4)CH2 and -C(4)H), 4.70 – 4.75 (br s, 1H, -C(5)H), 7.47 (d, 2H, J = 8.21 Hz, arom. H), 
7.78(d, 2H, J = 8.21 Hz, arom. H); 13C (75 MHz; DMSO-d6) δ: 20.77, 25.40, 26.67, 27.77, 
61.52, 61.79, 65.37, 65.92, 67.26, 68.11, 77.52, 80.13, 80.44, 82.40, 95.22, 95.54, 127.65, 
130.30, 131.85, 145.29, 150.26, 150.87; exact mass (ESI-MS) calculated for C20H27NO6SNa 
[M+Na]+: 432.1457, found: 432.1453. 
 
4.1.14.  ((4R,5R)-3-(tert-Butoxycarbonyl)-2,2-dimethyl-5-(2-phenylethynyl)oxazolidin-4-
yl)methyl 4-methylbenzenesulfonate (10b) 
 
128 mg (64%).  1H (300 MHz; DMSO-d6) δ: 1.33 (s, 9H, tert-butyl), 1.41 (s, 3H, -CH3), 1.65 
(s, 3H, –CH3), 2.38 (s, 3H, tosyl –CH3), 4.04 – 4.22 (m, 3H, -C(4)CH2 and -C(4)H), 4.93 – 
5.20 (m, 1H, -C(5)H), 7.34 – 7.44 (m, 5H, arom. H), 7.47 (d, 2H, J = 8.21 Hz, arom. H tosyl), 
7.78 (d, 2H, J = 8.21 Hz, arom. H tosyl); 13C (75 MHz; DMSO-d6) δ: 21.12, 25.56, 25.62, 
26.88, 27.17, 27.83, 61.53, 61.85, 66.07, 66.63, 67.35, 68.20, 80.18, 80.48, 85.55, 87.84, 
95.16, 95.58, 121.21, 127.74, 128.84, 130.36, 131.37, 131.88, 145.37, 150.37, 150.97; exact 
mass (ESI-MS) calculated for C26H32O6NS [M+H]+: 486.1950 found: 486.1956. 
 
General procedure for the preparation of 11a-d.  The secondary amine (4 mmol) was 
added to a solution of 10a-b (0.25 mmol) in anhydrous DMF (3 mL) and the mixture was 
heated at 45°C for 72 h.  The residue, resulting from removal of the solvent in vacuo, was 
purified by column chromatography (hexanes:EtOAc 4:1 for 11a-b, CH2Cl2:MeOH 99:1 for 
11c-d) yielding 11a-d as slightly brown solids. 
 
4.1.15.  (4R,5R)-tert-Butyl 2,2-dimethyl-4-(morpholinomethyl)-5-(2-
phenylethynyl)oxazolidine-3-carboxylate (11a) 
 
65 mg (62%).  1H (300 MHz; DMSO-d6) δ: 1.43 (s, 9H, tert-butyl), 1.48 (s, 3H, -CH3), 1.71 
(s, 3H, –CH3), 2.32 – 2.46 (m, 4H, CH2-N-CH2 morpholine), 2.50 – 2.62 (m, 2H, -C(4)CH2), 
3.50 – 3.65 (m, 4H, CH2-O-CH2 morpholine), 3.98 – 4.18 (m, 1H, -C(4)H), 4.96 – 5.05 (m, 
1H, -C(5)H), 7.36 – 7.47 (m, 5H, arom. H); 13C (75 MHz; DMSO-d6) δ: 25.77, 27.41, 28.04, 
53.70, 60.20, 61.06, 66.26, 68.24, 79.65, 82.07, 85.08, 94.87, 121.52, 128.85, 129.13, 131.36, 
150.60; exact mass (ESI-MS) calculated for C23H33O4N2 [M+H]+: 401.2440, found: 401.2439. 
 
4.1.16.  (4R,5R)-tert-Butyl 2,2-dimethyl-5-(2-phenylethynyl)-4-((piperidin-1-
yl)methyl)oxazolidine-3-carboxylate (11b)  
 
347 mg (85%).  1H (300 MHz; DMSO-d6) δ: 1.30 – 1.54 (m, 18H, tert-butyl, –CH3, CH2-
CH2-CH2 piperidine), 1.68 – 1.72 (s, 3H, -CH3), 2.23 – 2.60 (m, 6H, -C(4)CH2 and CH2-N-
CH2 piperidine), 4.92 – 4.16 (br s, 1H, -C(4)H), 4.82 - 5.04 (br s, 1H, -C(5)H), 7.34 – 7.45 
(m, 5H, arom. H); 13C (75 MHz; DMSO-d6) δ: 23.84, 25.57, 27.02, 27.38, 27.97, 28.97, 
54.55, 60.37, 61.60, 68.24, 79.51, 84.97, 89.31, 94.87, 121.49, 128.77, 129.04, 131.28, 
150.59; exact mass (ESI-MS) calculated for C24H35O3N2 [M+H]+: 399.2648, found: 399.2640. 
 
4.1.17.  (4R,5R)-tert-Butyl 2,2-dimethyl-5-(2-phenylethynyl)-4-((pyrrolidin-1-
yl)methyl)oxazolidine-3-carboxylate (11c) 
 
187 mg (82%).  1H (300 MHz; DMSO-d6) δ: 1.40 (s, 9H, tert-butyl), 1.44 (s, 3H, -CH3), 1.64 
– 1.74 (m, 7H, CH2-CH2-CH2-CH2 pyrrolidine and -CH3), 2.20 – 2.90 (br s, 5H, CH2-N-CH2 
pyrrolidine and –C(4)CHa), 3.23 – 3.34 (m, 1H, –C(4)CHb), 3.95 – 4.21 (m, 1H, –C(4)H), 
4.82 – 5.20 (br s, 1H, –C(5)H), 7.32 – 7.44 (m, 5H, arom. H); 13C (75 MHz; DMSO-d6) δ: 
23.12, 25.70, 27.43, 27.97, 53.80, 56.25, 57.58, 61.82, 62.47, 67.33, 67.96, 79.57, 79.95, 
85.06, 89.14, 94.63, 94.93, 121.52, 128.76, 129.04, 131.28, 150.61, 151.00; exact mass (ESI-
MS) calculated for C23H33O3N2 [M+H]+: 385.2491, found: 385.2487. 
 
Sonogashira coupling of 11d with iodobenzene.  An identical procedure as for the 
conversion of 9a to 9b gave 11c (290 mg, 93%) as a slightly brown solid. 
 
4.1.18.  (4R,5R)-tert-Butyl 5-ethynyl-2,2-dimethyl-4-((pyrrolidin-1-yl)methyl)oxazolidine-
3-carboxylate  (11d) 
 
1.18 g (89%).  1H (300 MHz; DMSO-d6) δ: 1.48 – 1.52 (m, 12H, tert-butyl and –CH3), 1.60 – 
1.70 (m, 7H, –CH3 and CH2-CH2-CH2-CH2 pyrrolidine), 2.30 – 2.60 (m, 6H, CH2-N-CH2 
pyrrolidine and –C(4)CH2), 3.57 (d, 1H, J = 2.34 Hz, alkyne H), 3.86 – 4.00 (m, 1H, -C(4)H), 
4.68 – 4.73 (br s, 1H, -C(5)H); 13C (75 MHz; DMSO-d6) δ: 23.16, 25.51, 27.49, 27.96, 53.71, 
57.62, 62.59, 67.23, 76.77, 79.48, 83.72, 94.97, 150.62; exact mass (ESI-MS) calculated for 
C17H29O3N2 [M+H]+: 309.2178, found: 309.2180. 
 
4.1.19.  (4R,5R)-tert-Butyl 4-(azidomethyl)-2,2-dimethyl-5-(2-phenylethynyl)oxazolidine-
3-carboxylate (11e) 
 
NaN3 (268 mg, 4.12 mmol, 10 eq.) was added to a solution of 10b (200 mg, 0.412 mmol) in 
anhydrous DMF (10 mL) and the mixture was heated at 45°C for 72 h.  After removal of the 
solvent under reduced pressure, the residue was purified by flash chromatography 
(hexanes:EtOAc 97:3) rendering 11e (145 mg, 99%) as a white solid.  1H (300 MHz; DMSO-
d6) δ: 1.43 (s, 9H, tert-butyl), 1.50 (s, 3H, -CH3), 1.69 (s, 3H, -CH3), 3.45 – 3.78 (m, 2H, -
C(4)CH2), 4.00 – 4.14 (br s, 1H, -C(4)H), 4.96 (d, 1H, J = 2.93 Hz, -C(5)H), 7.34 – 7.46 (m, 
5H, arom. H); 13C (75 MHz; DMSO-d6) δ: 25.37, 26.89, 27.83, 49.97, 51.15, 62.56, 66.69, 
67.28, 85.56, 87.56, 95.37, 121.30, 128.68, 129.08, 131.31, 150.48; exact mass (ESI-MS) 
calculated for C19H25N4O3 [M+H]+: 357,1927, found: 357,1929. 
 
General procedure for the preparation of 13a-d and 18.  A solution of oxazolidines 11a-e 
(0.8 mmol) in a mixture of MeOH/3N HCl (1:2, 30 mL) was heated at 50°C for 12 h and the 
solvent was subsequently removed under reduced pressure.  The residue was covered with 
chloroform (3 x 20 mL) and the volatiles evaporated thereby quantitatively affording crude 
amines 12a-d and 17 as their hydrochloride salts which were used without further 
purification. 
To a cooled solution (0°C) of crude amines 12a-d and 17 (0.8 mmol) and HOBT (10 mol %) 
in anhydrous pyridine (25 mL), p-nitrophenylpalmitate (0.8 mmol) dissolved in anhydrous 
DMF (5 mL) was added dropwise and the mixture was heated for 48 h at 50°C.  The solvent 
was subsequently removed under reduced pressure and the residue was purified by column 
chromatography (hexanes:EtOAc:TEA 65:34:1 for 13a-c and 18; hexanes:EtOAc 7:3 for 13d) 
producing 13a-d and 18 as colourless solids. 
 
4.1.20.  N-((2R,3R)-3-Hydroxy-1-morpholino-5-phenylpent-4-yn-2-yl)palmitamide (13a) 
 
232 mg (67%).  1H (300 MHz; CDCl3-d1) δ: 0.81 (t, 3H, J = 6.52 Hz, -CH3 acyl), 1.10 – 1.30 
(m, 24H, acyl H), 1.50 – 1.63 (m, 2H, -COCH2-CH2-C13H27), 2.14 (t, 2H, J = 7.50 Hz, -CO-
CH2-C14H29), 2.45 – 2.80 (m, 5H, -C(1)Ha and CH2-N-CH2 morpholine), 2.58 (dd, 1H, J = 
10.81 and 11.57 Hz, -C(1)Hb), 3.63 – 3.74 (m, 4H, CH2-O-CH2 morpholine), 4.41 – 4.54 (m, 
1H, -C(2)H), 4.72 (d, 1H, J = 3.73 Hz, -C(3)H), 5.55 – 5.90 (m, 1H, -NH), 7.31 – 7.40 (m, 
5H, arom. H); 13C (75 MHz; CDCl3-d1) δ: 13.12, 13.17, 20.06, 21.68, 24.62, 28.19, 28.34, 
28.45, 28.63, 28.67, 30.90, 35.72, 46.00, 52.88, 58.61, 65.25, 65.55, 85.58, 86.08, 121.06, 
127.39, 127.79, 130.78, 172.18; exact mass (ESI-MS) calculated for C31H51O3N2 [M+H]+: 
499.3899, found: 499.3902. 
 
4.1.21.  N-((2R,3R)-3-Hydroxy-5-phenyl-1-(piperidin-1-yl)pent-4-yn-2-yl)palmitamide 
(13b) 
 
227 mg (48%).  1H (300 MHz; DMSO-d6) δ: 0.83 (t, 3H, J = 0.83 Hz, -CH3 acyl), 1.12 – 1.29 
(m, 24H, acyl H), 1.30 – 1.40 (m, 2H, -COCH2-CH2-C13H27), 1.41 – 1.53 (m, 6H, CH2-CH2-
CH2 piperidine), 2.09 (t, 2H, J = 6.98 Hz, -CO-CH2-C14H29), 2.32 – 2.45 (m, 5H, -C(1)Ha, 
CH2-N-CH2 piperidine), 2.65 (dd, 1H, J = 6.74 and 12.61 Hz, -C(1)Hb), 4.04 – 4.14 (m, 1H, -
C(2)H), 4.56 (d, 1H, J = 3.52 Hz, -C(3)H), 5.80 – 6.20 (br s, 1H, -C(3)OH), 7.31 – 7.42 (m, 
5H, arom. H), 7.60 – 7.65 (d, 1H, J = 8.21 Hz, -NH); 13C (75 MHz; DMSO-d6) δ: 13.93, 
22.08, 23.76, 25.52, 28.48, 28.69, 28.86, 28.93, 28.99, 29.02, 31.28, 35.38, 50.08, 54.23, 
58.11, 62.20, 83.74, 90.04, 122.51, 128.37, 128.49, 131.35, 172.25; exact mass (ESI-MS) 
calculated for C32H53O2N2 [M+H]+: 497.4107, found: 497.4101. 
 
4.1.22.  N-((2R,3R)-3-Hydroxy-5-phenyl-1-(pyrrolidin-1-yl)pent-4-yn-2-yl)palmitamide 
(13c) 
 
129 mg (45%).  1H (300 MHz; DMSO-d6) δ: 0.83 (t, 3H, J = 7.03 Hz, -CH3 acyl), 1.12 – 1.28 
(m, 24H, acyl H), 1.42 – 1.51 (m, 2H, -COCH2-CH2-C13H27), 1.62 – 1.68 (m, 4H, CH2-CH2 
pyrrolidine), 2.09 (dt, 2H, J = 2.93 and 7.04 Hz, -CO-CH2-C14H29), 2.41 – 2.53 (m, 5H, -
C(1)Ha and CH2-N-CH2 pyrrolidine), 2.76 (dd, 1H, J = 5.57 and 12.02 Hz, -C(1)Hb), 4.05 
(ddd, 1H, J = 3.81, 7.92 and 11.43 Hz, -C(2)H), 4.57 (d, 1H, J = 3.81 Hz, -C(3)H), 5.75 – 
5.87 (br s, 1H, -OH), 7.31 – 7.40 (m, 5H, arom. H), 7.60 (d, 1H, J = 8.50 Hz, -NH); 13C (75 
MHz; DMSO-d6) δ: 13.88, 22.02, 23.13, 25,47, 28.45, 28.63, 28.80, 28.88, 28.96, 31.22, 
35.35, 51.94, 53.72, 55.11, 62.00, 86.57, 90.12, 122.53, 128.28, 128.43, 131.29, 172.19; exact 
mass (ESI-MS) calculated for C31H51O2N2 [M+H]+: 483.3951, found: 483.3953. 
 
Sonogashira coupling of 18 with iodobenzene.  An identical procedure as for the conversion 
of 9a to 9b gave 13c (19 mg, 32%) as a colourless solid. 
 
4.1.23.  N-((2R,3R)-1-Azido-3-hydroxy-5-phenylpent-4-yn-2-yl)palmitamide (13d) 
 
351 mg (62%).  1H (300 MHz; DMSO-d6) δ: 0.83 (t, 3H, J = 6.65 Hz, -CH3 acyl), 1.10 – 1.30 
(m, 24H, acyl H), 1.42 – 1.54 (m, 2H, -COCH2-CH2-C13H27), 2.12 (dt, 2H, J = 2.64 and 7.04 
Hz, -CO-CH2-C14H29), 3.45 (dd, 1H, J = 8.79 and 12.60 Hz, -C(1)Ha), 3.53 (dd, 1H, J = 4.69 
and 12.60 Hz, -C(1)Hb), 4.02 – 4.12 (m, 1H, -C(2)H), 4.53 (app. t, 1H, J = 4.83 Hz, -C(3)H), 
5.89 (d, 1H, J = 5.57 Hz, -C(3)OH), 7.32 – 7.44 (m, 5H, arom. H), 7.96 (d, 1H, J = 8.50 Hz, -
NH); 13C (75 MHz; DMSO-d6) δ: 13.93, 13.93, 22.08, 25.34, 28.53, 28.69, 28.83, 28.91, 
28.98, 29.01, 31.28, 35.41, 50.11, 53.23, 54.90, 61.43, 84.25, 88.89, 122.21, 128.51, 128.56, 
131.40, 172.65; exact mass (ESI-MS) calculated for C27H43O2N4 [M+H]+: 455.3386, found: 
455.3380.  
 
4.1.24.  N-((2R,3R)-3-Hydroxy-1-(pyrrolidin-1-yl)pent-4-yn-2-yl)palmitamide (18) 
 
71 mg (60%).  1H (300 MHz; DMSO-d6) δ: 0.82 (t, 3H, J = 6.74 Hz, -CH3 acyl), 1.12 – 1.30 
(m, 24H, acyl H), 1.38 – 1.50 (m, 2H, -COCH2-CH2-C13H27), 1.58 – 1.66 (m , 4H, -CH2-CH2- 
pyrrolidine), 2.06 (t, 2H, J = 7.62 Hz, -CO-CH2-C14H29), 2.37 – 2.45 (m, 5H, -C(1)Ha and 
CH2-N-CH2 pyrrolidine), 2.68 (dd, 1H, J = 5.86 and 12.02, -C(1)Hb), 3.18 (d, 1H, J = 2.34 
Hz, alkyne H), 3.86 – 3.96 (m, 1H, -C(2)H), 4.32 (dd, 1H, J = 1.76 and 3.82 Hz, -C(3)H), 
7.54 (d, 1H, J = 8.21 Hz, -NH); 13C (75 MHz; DMSO-d6; hydrochloride salt of 18) δ: 14.36, 
23.33, 23.68, 23.89, 26.31, 26.47, 30.00, 30.18, 30.25, 30.42, 30.61, 32.64, 36.79, 51.38, 
52.98, 53.63, 55.13, 63.15, 86.00, 88.42, 174.27; exact mass (ESI-MS) calculated for 
C25H47O2N2 [M+H]+: 407.3638, found: 407.3632. 
 
4.1.25.  N-((2R,3R)-1-Amino-3-hydroxy-5-phenylpent-4-yn-2-yl)palmitamide (13e) 
 
To a solution of 13d (51.4 mg, 0.113 mmol) in THF (250 µL), PPh3 (59 mg, 0.226 mmol, 2 
eq.) was added.  After stirring for 10 min at room temperature, H2O (250 µL) was added and 
stirring was continued for 48 h.  After removal of the solvent under reduced pressure, the 
residue was purified by flash chromatography (CH2Cl2:MeOH(10% 6N NH3 in MeOH) 9:1) 
affording  13e (47 mg, 97%) as a white solid.  1H (300 MHz; DMSO-d6) δ: 0.83 (t, 3H, -CH3 
acyl), 1.11 – 1.28 (m, 24H, acyl H), 1.41 – 1.53 (m, 2H, -COCH2-CH2-C13H27), 2.02 – 2.19 
(m, 2H, -CO-CH2-C14H29), 2.68 (dd, 1H, J = 7.62 and 12.90 Hz, -C(1)Ha), 2.85 (dd, 1H, J = 
6.16 and 12.90 Hz, -C(1)Hb), 3.10 - 3.50 (br s, 2H, -NH2), 3.76 – 3.88 (m, 1H, -C(2)H), 4.64 
(d, 1H, J = 4.11 Hz, -C(3)H), 7.31 – 7.42 (m, 5H, arom. H), 7.61 (d, 1H, J = 8.50 Hz, -NH); 
13C (75 MHz; DMSO-d6) δ: 13.95, 22.08, 25.51, 28.57, 28.69, 28.86, 28.93, 29.02, 31.28, 
38.96, 54.90, 55.25, 61.74, 83.74, 90.13, 122.53, 128.36, 128.50, 131.31, 172.60; exact mass 
(ESI-MS) calculated for C27H45O2N2 [M+H]+: 429.3481, found: 429.3483. 
 
General procedure for the reduction of 13a, 13c and 13e.  Red-Al® (4 mmol) was added to 
a cooled (-78°C) solution of 13a, 13c or 13e (0.4 mmol) in anhydrous Et2O (10 mL), and the 
resulting mixture was stirred overnight at room temperature.  After quenching the reaction 
(0°C) by addition of MeOH (10 mL), sat. disodiumtartrate (20 mL) was added, and the 
mixture was stirred for an additional 4 h.  Et2O (25 mL) and sat. NaHCO3 (25 mL) were 
added, the aqueous layer was extracted with Et2O (3 x 25 mL) and the combined organic 
phase was dried over MgSO4.  Flash chromatography (hexanes:EtOAc:TEA 60:39:1 for 14a 
and 14b, CH2Cl2:MeOH (5% 6N NH3 in MeOH) 4:1 for 14c) afforded 14a-c as colourless 
oils. 
 
4.1.26.  (E,3R,4R)-4-(Hexadecylamino)-5-morpholino-1-phenylpent-1-en-3-ol (14a) 
 
115 mg (60%).  1H (300 MHz; DMSO-d6 + D2O) δ: 0.83 (t, 3H, J = 6.70 Hz, -CH3 alkyl), 
1.12 – 1.42 (m, 28H, alkyl H), 2.19 (dd, 1H, J = 7.62 and 12.31 Hz, -C(5)Ha), 2.24 – 2.42 (m, 
5H, CH2-N-CH2 morpholine and -C(5)Hb), 2.58 (dt, 2H, J = 2.35 and 7.04 Hz, -NH-CH2-
C15H31), 2.68 – 2.75 (m, 1H, -C(4)H), 3.52 (t, 4H, J = 4.69 Hz, CH2-O-CH2 morpholine), 4.17 
(app. t, 1H, J = 3.81 Hz, -C(3)H), 6.38 (dd, 1H, J = 5.28 and 15.83 Hz, -C(2)H), 6.53 (d, 1H, 
J = 15.83 Hz, -C(1)H), 7.15 – 7.40 (m, 5H, arom); 13C (75 MHz; DMSO-d6) δ: 13.94, 22.08, 
26.64, 28.68, 28.86, 28.99, 29.74, 31.28, 47.74, 53.70, 58.77, 59.19, 66.32, 71.36, 126.07, 
127.04, 128.43, 128.55, 132.05, 137.06; exact mass (ESI-MS) calculated for C31H55O2N2 
[M+H]+: 487.4264, found: 487.4268. 
 
4.1.27.  (E,3R,4R)-4-(Hexadecylamino)-1-phenyl-5-(pyrrolidin-1-yl)pent-1-en-3-ol (14b) 
 
130 mg (100%).  1H (300 MHz; CDCl3-d1) δ: 0.88 (t, 3H, J = 6.66 Hz, -CH3 alkyl), 1.41 – 
1.51 (m, 26H, alkyl H), 1.32 – 1.42 (m, 2H, -NHCH2-CH2-C14H29), 1.75 – 1.83 (m, 4H, CH2-
CH2 pyrrolidine), 2.56 – 2.77 (m, 8H, -C(5)H2, -NH-CH2-C15H31 and CH2-N-CH2 
pyrrolidine), 2.93 (dt, 1H, J = 4.17 and 6.99 Hz, -C(4)H), 4.16 (app. t, 1H, J = 4.90 Hz, -
C(3)H), 6.30 (dd, 1H, J = 5.43 and 15.93 Hz, -C(2)H), 6.71 (dd, 1H, J = 1.03 and 15.92 Hz, -
C(1)H), 7.20 – 7.43 (m, 5H, arom. H); 13C (75 MHz; CDCl3-d1) δ: 14.12, 22.69, 23.59, 27.19, 
29.36, 29.49, 29.61, 29.69, 30.23, 31.92, 48.63, 54.51, 57.69, 59.53, 73.20, 126.64, 127.35, 
128.50, 130.49, 130.66, 137.11; exact mass (ESI-MS) calculated for C31H55ON2 [M+H]+: 
471.4314, found: 471.4308. 
 
4.1.28.  (E,3R,4R)-5-Amino-4-(hexadecylamino)-1-phenylpent-1-en-3-ol (14c) 
 
136 mg (45%).  1H (300 MHz; DMSO-d6 + D2O) δ: 0.83 (t, 3H, J = 6.73 Hz, -CH3 alkyl), 
1.15 – 1.30 (m, 26H, alkyl H), 1.33 – 1.40 (m, 2H, -NHCH2-CH2-C14H29), 2.36 – 2.73 (m, 5H, 
-C(5)H2, -NH-CH2-C15H31 and –C(4)H), 4.35 (app. t, 1H, J = 4.06 Hz, -C(3)H), 6.33 (dd, 1H, 
J = 5.61 and 16.00 Hz, -C(2)H), 6.55 (d, 1H, J = 16.14 Hz, -C(1)H), 7.16 – 7.42 (m, 5H, 
arom. H); 13C (75 MHz; DMSO-d6) δ: 13.94, 22.08, 26.78, 28.69, 29.07, 30.07, 31.28, 37.02, 
47.38, 57.84, 64.91, 71.55, 126.10, 127.09, 128.54, 128.74, 132.13, 137.03; exact mass (ESI-
MS) calculated for C27H49ON2 [M+H]+: 417.3845, found: 417.3844. 
 
 
General procedure for the preparation of ceramides 16a-c.  Applying an identical 
procedure as described for the reduction of amides 13a, 13c and 13e with Red-Al® 
quantitatively produced crude E-alkene amines 15a-c as their hydrochloride salts, which were 
used without further purification.   
An identical procedure as for the acylation of amines 12a-d and 17 with palmitoyl chloride 
afforded ceramides 16a-c as colourless oils. 
 
4.1.29.  N-((E,2R,3R)-3-Hydroxy-1-morpholino-5-phenylpent-4-en-2-yl)palmitamide 
(16a) 
 
201 mg (84%).  1H (300 MHz; DMSO-d6) δ: 0.84 (t, 3H, J = 6.70 Hz, -CH3 acyl), 1.09 – 1.30 
(m, 24H, acyl H), 1.36 – 1.48 (m, 2H, -COCH2-CH2-C13H27), 2.04 (t, 2H, J = 7.47 Hz, -CO-
CH2-C14H29), 2.21 – 2.42 (m, 5H, -C(1)Ha and CH2-N-CH2 morpholine), 2.54 – 2.64 (m, 1H, 
-C(1)Hb), 3.48 – 3.54 (m, 4H, CH2-O-CH2 morpholine), 4.00 – 4.12 (m, 1H, -C(2)H), 4.24 – 
4.32 (m, 1H, -C(3)H), 5.21 (d, 1H, J = 4.69 Hz, -C(3)OH) 6.23 (dd, 1H, J = 4.98 and 15.83 
Hz, -C(4)H), 6.47 – 6.56 (dd, 1H, J = 1.18 and 15.83 Hz, -C(5)H), 7.11 – 7.37 (m, 5H, arom. 
H), 7.46 (d, 1H, J = 9.09 Hz, -NH); 13C (75 MHz; DMSO-d6) δ: 14.02, 22.16, 25.61, 28.55, 
28.77, 29.91, 28.99, 29.09, 35.49, 49.86, 53.56, 58.63, 66.29, 70.71, 126.18, 127.07, 128.16, 
128.19, 128.45, 128.81, 131.29, 136.99, 172.02; exact mass (ESI-MS) calculated for 
C31H53O3N2 [M+H]+: 501.4056, found: 501.4058. 
 
4.1.30.  N-((E,2R,3R)-3-Hydroxy-5-phenyl-1-(piperidin-1-yl)pent-4-en-2-yl)palmitamide 
(16b) 
 
217 mg (78%).  1H (300 MHz; DMSO-d6) δ: 0.83 (app. t, 3H, J = 6.78 Hz, -CH3 acyl), 1.09 – 
1.30 (m, 32H, acyl chain and CH2-CH2-CH2 piperidine), 2.04 (t, 2H, J = 7.03 Hz, -CO-CH2-
C14H29), 2.16 – 2.25 (dd, 1H, J = 4.69 and 12.02 Hz, -C(1)Ha), 2.25 – 2.38 (m, 4H, -CH2-N-
CH2 piperidine), 2.42 – 2.50 (m, 1H, -C(1)Hb), 4.00 – 4.10 (m, 1H, -C(2)H), 4.24 – 4.30 (m, 
1H, -C(3)H), 5.20 -5.40 (br s, 1H -C(3)OH) 6.23 (dd, 1H, J = 4.99 and 15.83 Hz, -C(4)H), 
6.51 (dd, 1H, J = 1.17 and 15.83 Hz, -C(5)H), 7.05 – 7.38 (m, 5H, arom. H), 7.43 (d, 1H, J = 
8.79 Hz, -NH); 13C (75 MHz; DMSO-d6) δ: 13.94, 22.09, 23.99, 25.54, 25.68, 28.49, 28.70, 
28.85, 28.93, 28.99, 29.03, 31.29, 31.79, 35.46, 50.01, 54.31, 58.92, 70.91, 126.12, 127.06, 
128.16, 128.21, 128.46, 128.78, 131.39, 137.05, 171.91; exact mass (ESI-MS) calculated for 
C32H55O2N2 [M+H]+: 499.4263, found: 499.4258. 
 
4.1.31.  N-((E,2R,3R)-3-Hydroxy-5-phenyl-1-(pyrrolidin-1-yl)pent-4-en-2-yl)palmitamide 
(16c) 
 
175 mg (71%).  1H (300 MHz; DMSO-d6) δ: 0.79 – 0.88 (app. t, 3H, -CH3 acyl), 1.09 – 1.30 
(m, 24H, acyl chain), 1.34 – 1.48 (m, 2H, -COCH2-CH2-C13H27), 1.58 – 1.69 (m, 4H, CH2-
CH2 pyrrolidine), 2.04 (dt, 2H, J = 3.52 and 7.04 Hz, -CO-CH2-C14H29), 2.33 (dd, 1H, J = 
7.62 and 12.02 Hz, -C(1)Ha), 2.38 – 2.46 (m, 4H, CH2-N-CH2 pyrrolidine), 2.65 (dd, 1H, J = 
6.45 and 12.02 Hz, -C(1)Hb), 3.96 – 4.07 (m, 1H, -C(2)H), 4.26 – 4.33 (m, 1H, -C(3)H), 6.24 
(dd, 1H, J = 4.98 and 15.83 Hz, -C(4)H), 6.52 (dd, 1H, J = 1.18 and 15.84 Hz, -C(5)H), 7.10 – 
7.38 (m, 5H, arom.), 7.45 (d, 1H, J = 8.80 Hz, -NH); 13C (75 MHz; DMSO-d6) δ: 13.94, 
22.08, 23.15, 25.52, 28.48, 28.69, 28.83, 28.91, 28.99, 29.02, 31.28, 35.44, 51.77, 53.75, 
55.85, 70.73, 126.11, 127.05, 128.16, 128.73, 128.45, 128.73, 131.37, 137.04, 171.97; Exact 
mass (ESI-MS) calculated for C31H53O2N2 [M+H]+: 485.4107, found: 485.4109 
 
4.1.32.  N-((5R,6R)-2-Oxo-6-(2-phenylethynyl)-1,3-oxazinan-5-yl)palmitamide (19) 
To a cooled solution (0°C) of 13e (64 mg, 149 µmol) and TEA (83 µL, 596 µmol, 4 eq.) in 
anhydrous CH2Cl2 (10 mL), triphosgene (46.5 mg, 156 µmol, 1.05 eq.) dissolved in CH2Cl2 
(1 mL) was added dropwise and the resulting solution was stirred for 1 h at room temperature.  
After removal of the solvent under reduced pressure, the mixture was purified by column 
chromatography (EtOAc) affording 19 (60 mg, 88%) as a white solid.  1H (500 MHz; DMSO-
d6) δ: 0.85 (t, 3H, J = 7.00 Hz, -CH3 acyl), 1.1 – 1.3 (m, 24H, acyl H), 1.48 (m, 2H, -COCH2-
CH2-C13H27), 2.16 (dt, 1H, J = 7.33 and 13.91 Hz, -CO-CHa-C14H29), 2.20 (dt, 1H, J = 7.32 
and 13.91 Hz, -CO-CHb-C14H29 ), 3.19 (ddd, 1H, J = 2.19, 6.71 and 11.60 Hz -C(4)Ha), 3.40 
(ddd, 1H, J = 2.07, 5.13 and 11.60 Hz, -C(4)Hb), 4.36 (dddd, 1H, J = 3.66, 5.13, 6.59, and 
7.81 Hz, -C(5)H), 5.41 (d, 1H, J = 3.42 Hz, -C(6)H), 7.40 (obsolete, -C(3)NH), 7.35 – 7.50 
(m, 5H, arom. H), 8.33 (d, 1H, J = 7.82 Hz, -C(3)NH); 13C (125 MHz; DMSO-d6) δ: 13.99, 
22.17, 25.53, 28.67, 28.79, 28.94, 28.96, 29.11, 31.37, 35.18, 41.99, 43.13, 68.12, 83.86, 
86.81, 121.32, 128.67, 129.27, 131.72, 151.08, 172.98; exact mass (ESI-MS) calculated for 
C28H43N2O3 [M+H]+: 455.3274 found: 455.3275. 
 
4.2.  In vitro analysis of GlcCer synthase  
 
In vitro analysis of GlcCer synthase was performed in rat Golgi membranes using N-[6-[(7-
nitrobenzo-2-oxa-1,3-diazol-4-yl)amino]hexanoyl]D-erythro-sphingosine (C6-NBD-D-
erythro-Cer). C6-D-erythro-NBD ceramide was synthesized by N-acylation of sphingosine 
using the NHS-ester of NBD-hexanoic acid (Molecular Probes).18 
 
A Golgi fraction was isolated from rat liver by the method of Dominguez et al.,19 as follows. 
Rat liver was homogenized in ice-cold 0.25 M sucrose, 50 mM Tris-HCl, pH 7.4, 25 mM 
KCl, 5 mM MgCl2, 4.5 mM CaCl2 (STKCM buffer) using a motorized Potter-Elvehjem 
homogenizer. After centrifugation at 400g for 10 min, supernatants were adjusted to 0.2 M 
sucrose in STKCM buffer and underlayed beneath a discontinuous gradient of 0.9 and 0.4 M 
sucrose in STKCM buffer. After centrifugation at 83000 gav for 3 h in a SW 32 rotor at 4oC, 
Golgi fractions were collected at the 0.4/0.9 M sucrose interface. 
 
The in vitro reaction mixture contained a rat liver Golgi fraction (1.6 µg of protein), UDP-
glucose (5 mM), C6-NBD-D-erythro-ceramide (5 µM), MnCl2 (5 mM), and protease 
inhibitors in a total volume of 1 ml of TK buffer (50 mM Tris-HCl, 25 mM KCl, pH 7.4). The 
reactions were allowed to proceed for 20 min at 37°C, and were terminated by addition of 3 
ml of chloroform/methanol (1:2 v/v). Lipids were extracted20 and separated by thin-layer 
chromatography using chloroform/methanol/9.8 mM CaCl2 (60:35:8, v/v/v) as the developing 
solvent. C6-NBD-sphingolipids were identified using authentic standards. C6-NBD-
fluorescence was quantified by Quantity One software after exposing the TLC plates using a 
Fluor-S Max spectrometer (BioRad). 
 
4.3.  Analysis of GlcCer synthase activity in living cells 
 
Human embryonic kidney HEK-293 cells were grown to 80-90% confluency.  C6-NBD-D-
erythro-Ceramide was added directly to the culture dishes, together with 10, 25, and 50 µM of 
inhibitors.  Cells were incubated for 3 hours at 37°C in a 5% CO2 incubator.  At the end of the 
incubation, dishes were washed with PBS, and cells removed by scraping with a rubber 
stirring rod into ice-cold water.  Lipids were extracted,20 separated and quantified as above.  
 
4.4.  3H-serine labeling 
  
Dishes, containing HEK-293 and COS-7 cells, were incubated for 1 hour  with 50 mM of 
compounds 18 and 16c, followed by addition of L-[3-3H]-serine (Amersham) (30 µCi in 3 ml 
medium) for another 3 hours. At the end of the incubation, dishes were washed with PBS, 
cells removed by scraping with a rubber stirring rod into ice-cold water, and lipids extracted.20 
Phospholipids were degraded by mild alkaline hydrolysis with methanolic NaOH (100mM) 
for 2 h at 37°C. Lipid extracts were desalted by Sephadex G-25 (superfine, Sigma),21 and 
separated by TLC using chloroform/methanol/9.8 mM CaCl2 (60:35:8, v/v/v) as the 
developing solvent. Sphingolipids were visualized by spraying with cupric sulfate, followed 
by brief charring. Ceramide, glucosylceramide, lactosylceramide, and sphingomyelin were 
identified using authentic standards. Corresponding bands were scraped from the TLC plates, 
radioactivity was recovered from silica in 1 ml of methanol, followed by addition of Ultima 
Gold scintillation cocktail. Radioactivity was determined by liquid scintillation counting.  
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Legends 
 
 
Figure 1.  Structures of GlcCer (1), D-threo-PDMP (2) and E-styryl-ceramides (3). 
 
Figure 2. Effects of inhibitors on GlcCer (A) and SM (B) synthesis assayed in vitro in Golgi 
fractions. The reactions were carried out in the presence or absence of varying concentrations 
of inhibitors.  
 
Figure 3. Effects of analogues 18 and 16c on GlcCer (A) and SM (B) synthesis measured in 
vitro in Golgi fractions.  The reactions were carried out in the presence and absence of various 
inhibitor concentrations. 
 
Figure 4.  Effects of analogues 18 and 16c on GlcCer (A) and SM (B) synthesis assayed in 
HEK-293 cells using C6-NBD-ceramide.  The reactions were carried out in the presence and 
absence of various inhibitor concentrations. 
 
Figure 5. Effects of 18 and 16c on de novo sphingolipid synthesis assayed using L-[3-3H]-
serine in HEK-293 cells.  Analyses were performed after 3 h incubation following 1 h pre-
treatment with 50 µM of the inhibitors. 
 Scheme 1.  Reagents and conditions: a) lithium trimethylsilylacetylide, ZnBr2, Et2O, -78°C to 
RT, overnight; b) TBAF, THF, RT, 1 h; c) lithiumphenylacetylide, ZnBr2, -78°C to RT, 
overnight; d) 90% acetic acid, 60°C, 5 h or p-TsOH, MeOH, RT, 36 h; e) TBDPSCl, 
imidazole, 4-DMAP, DMF, RT, 16 h; f) p-TsOH, Me2CO, 2,2-dimethoxypropane, reflux, 6 h; 
g) TBAF, THF, RT, 1 h; h) PdCl2(PPh3)2, iodobenzene, piperidine, 70°C, overnight; i) p-
TsCl, 4-DMAP, pyridine, 0°C to RT,  35 h; j) secondary amine, DMF, 45°C, 72 h. 
 
Scheme 2.  Reagents and conditions: a) 3N HCl, MeOH, 50°C, 12 h; b) p-
nitrophenylpalmitate, HOBT, pyridine, 50°C, 48 h; c) Red-Al, Et2O, -78°C to RT, overnight; 
d) PPh3, THF, RT for 30' then H2O, RT, 48 h; e) PdCl2(PPh3)2, iodobenzene, piperidine, 
70°C, overnight; f) triphosgene, TEA, CH2Cl2, 0°C to RT, 1h. 
 
Scheme 3.  Possible conformers of erythro/threo-19. 
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